CALM1 and cancer: showed that high levels of calmodulin 1 expression in gastric CAFs predict poor clinical outcomes in GC patients, and that calmodulin 1 can promote chemotherapy resistance in gastric cancer by increasing matrix stiffness mediated by cancer-associated fibroblasts (80).